ReviewInternational journal of nanomedicine2026
Research Progress on Mesenchymal Stem Cells-Derived Small Size Vesicles for the Treatment of Liver Diseases.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver disease is a major public health challenge, accounting for a substantial burden of mortality and morbidity worldwide. Currently, liver transplantation is the gold standard for treating end-stage liver diseases. However, it is affected by the shortage of organ sources and immune rejection. Mesenchymal stem cells (MSCs) can be used as an alternative therapy for liver diseases, especially in cases of liver cirrhosis, liver failure and complications of liver transplantation. However, MSCs may have potential effects on tumor occurrence. MSCs derived small size vesicles are nanoscale extracellular vesicles (EVs) which secreted by MSCs. MSCs derived small size vesicles are characterized by a lipid bilayer membrane, which encapsulate and transport various biomolecules such as proteins and miRNAs. Compared to MSCs, MSCs derived small size vesicles showed more advantages including lower tumor occurrence and lower toxicity. It has been found that MSCs derived small size vesicles ameliorate liver diseases via regulating lipid metabolism, inhibiting apoptosis, promoting regeneration, suppressing inflammation, drug delivery and so on. Based on the important role of MSCs derived small size vesicles in liver diseases treatment, this review aims to summarize the biological processes of small size vesicles with focusing on the effect of MSCs derived small size vesicles on different liver diseases. Additionally, we also discussed the potential future directions for small size vesicles research, including the challenges to be overcome and the prospects for clinical applications. This review provides theoretical support of MSCs derived small size vesicles as a potential therapeutic agent for liver disease in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.